My Photo

Mental Health

April 22, 2008

Infected with Insanity: Could Microbes Cause Mental Illness?: Scientific American

Link: Infected with Insanity: Could Microbes Cause Mental Illness?: Scientific American.

Bugs and the Brain Mental illnesses once thought to be the result of neurological or psychological defects may be caused by viral or microbial infections. The strongest evidence links schizophrenia to prenatal influenza infection; pregnant women who become ill with the flu are more likely to give birth to children who will develop schizophrenia. The body’s immune reaction, rather than the infections themselves, may be to blame for the resulting brain damage and psychiatric symptoms. Understanding the relation between infections and psychiatric disorders may someday allow us to prevent mental illness using drugs or vaccines.

March 31, 2008

Mental Health Insurance Parity - The Murky Politics of Mind-Body - New York Times

Link: Mental Health Insurance Parity - The Murky Politics of Mind-Body - New York Times.

This month, the House passed a bill that would require insurance companies to provide mental health insurance parity. It was the first time it has approved a proposal so substantial.

February 24, 2008

Daring to Think Differently About Schizophrenia - New York Times

Link: Daring to Think Differently About Schizophrenia - New York Times.

Dr. Schoepp and other scientists had focused their attention on the way that glutamate, a powerful neurotransmitter, tied together the brain’s most complex circuits. Every other schizophrenia drug now on the market aims at a different neurotransmitter, dopamine.

The Lilly results have fueled a wave of pharmaceutical industry research into glutamate. Companies are searching for new treatments, not just for schizophrenia, but also for depression and Alzheimer’s disease and other unseen demons of the brain that torment tens of millions of people worldwide

January 26, 2008

Lifting the Curtain on Depression - New York Times

Link: Lifting the Curtain on Depression - New York Times.

Depression is no monochromatic black veil, no shared melancholy, as is often claimed. Instead, the disorder is more like a virus that amplifies each sufferer’s particular vulnerabilities, whether anxiety, helplessness, self-doubt, anger or some combination of these. The subjective experience varies from person to person, yet treatment is far from personalized.

Test of Brain Device Is Setback for Maker - New York Times

Link: Test of Brain Device Is Setback for Maker - New York Times.

This short article is on the reported failing of an electronic device being tested to improve function after a stroke. The results may however demonstrate the value of providing aggressive physical therapy for all stroke victims.

January 17, 2008

Antidepressant Studies Unpublished - New York Times

Not an indictment of all anti-depressants, this investigative piece suggests that consumers (and their advocates) need to scrutinize drug maker's claim more closely about the effectiveness. 

Link: Antidepressant Studies Unpublished - New York Times.

The makers of antidepressants like Prozac and Paxil never published the results of about a third of the drug trials that they conducted to win government approval, misleading doctors and consumers about the drugs’ true effectiveness, a new analysis has found.

December 23, 2007

Talking Back to Prozac - The New York Review of Books

Link: Talking Back to Prozac - The New York Review of Books.

Frederick C. Crews is Professor of English Emeritus at the Berkeley. He is best known for two essays critiquing Freud, Freudian theory and the recovered memory movement.

In this excellent book review he takes on the scientific basis for our current thinking on depression as well as the influence of market forces on the increased diagnosis of the disease.

Additionally, the medicalization of personality traits is discussed in his critique of the book Shyness: How Normal Behavior Became a Sickness by Christopher Lane.

Continue reading "Talking Back to Prozac - The New York Review of Books" »

Nursing Homes and the use of Psychotropic Medication

A recent article in the Wall Street Journal ("Nursing Homes Struggle To Kick Drug Habit", December 20, 2007) discussed alternatives to using anti-psychotic medications to control the behaviors of older adults with dementia.  If your unfamiliar with why these drugs are administered at all, then here is a bit of background.

As dementia's progresses the confusion that accompanies the disease process can result in perceptions of danger and situations that make the afflicted individual fearful and distrustful, often mis-perceiving their environment and the intentions of those around them. Because these symptoms are associated with an altered state perception the resulting behaviors are often characterized as a psychosis

There has been much concern and debate about the use of anti-psychotic medications in older adults to treat behavioral symptoms.

The extreme of this argument on the Con side has been that anti-psychotics are chemical restraints and should be banned from use altogether. The opponents rightly understand that in many cases these uncomfortable symptoms are a response to environmental stimuli and can be controlled or reduced by proper attention to the environment in which people with dementia are cared for (and the behavior of their caregivers).

Proponents for the use of anti-psychotics in persons with dementia are often the mental health practitioners who are called by physicians and nurses in skilled nursing facilities or family members begging for some relief, both for the confused patient who seems to be in emotionally painful distress, as well as for those around them.

There is some evidence for concern about the use of these drugs in older adults. The Food and Drug Administration has issued a  "black box" warning labels that these drugs can increase the risk of death for elderly dementia sufferers.

The WSJ article describes alternative practices for treating persons with dementia that have helped reduce or eliminate the need for psychotropic medications. These are common sense solutions such as: creating an environment that reduces fear and anxiety, insuring consistency in caregivers (reduced turnover), allow time for the caregivers to get to know the individual older adult (their needs and preferences) and a focus on staff training on the special needs of the cognitively impaired. Sounds simple no? Then why isn't every nursing home and mental health professional in the country weaning all elders with dementia off the stuff?

Because there is no panacea and this issue like so many in long term care is complex. Changing the culture of long term care is slow and changing the environment of existing facilities is expensive. Retaining quality caregivers requires both money and a management's determination to value its staff and provide both monetary and non-monetary incentives for staying in a tough work environment. If all nursing homes were run by non-profits would things be better? That would depend on how non-profits decided to (or were required to) spend their money.  Both Shareholder's of for-profit facilities and Board Member's of non-profits need to make the decision if they are going to divert some of their revenue to accommodate the need for High Touch (rather than high tech).

And, as the article points out, the alternative methods do not always reduce confusion, fear, anxiety, or the undesired behaviors. However, there is no question that these alternatives work and should be the rule, rather than the exception.

Your thoughts?